Melinta Therapeutics, Inc. (NASDAQ:MLNT)

13.20
Delayed Data
As of Feb 23
 +0.30 / +2.33%
Today’s Change
10.25
Today|||52-Week Range
24.25
-16.46%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$413.5M

Company Description

Melinta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes antibiotics. Its product, Baxbela, is used in the treatment of acute bacterial skin and skin structure infections. The company was is headquartered in New Haven, CT.

Contact Information

Melinta Therapeutics, Inc.
300 George Street
New Haven Connecticut 06511
P:(312) 767-0291
Investor Relations:

Employees

Shareholders

Mutual fund holders9.18%
Other institutional16.65%
Individual stakeholders--

Top Executives

Daniel Mark WechslerPresident, Chief Executive Officer & Director
Paul EstremChief Financial Officer, Secretary & EVP
Sue CammarataChief Medical Officer & Executive Vice President
Erin M. DuffyChief Scientific Officer & Executive VP
Lyn BaranowskiSenior VP-Corporate Development & Strategy